AR and prostate cancer: In this study we examined the role of EN2 over-expression in the following prostate cancer cell lines: LNCaP, which is p53 wild-type and androgen receptor (AR) positive; DU145, which has a mutated p53 and is AR negative; and the p53-null line PC3, which is also AR negative.